Baylor Research Institute: Technology Transfer

Technology Transfer

Baylor Research Institute's (BRI) quest to bring innovative treatments from the laboratory workbench to the patient bedside often leads to commercially relevant inventions in the laboratory. BRI works closely with the scientists to determine when an invention is patentable, providing legal guidance and acting as the point of contact for companies interested in developing and commercializing the inventions.

To date, BRI has patented more than 40 inventions, while forming a biotech company, ODC Therapy, Inc.

ODC develops, produces, and distributes customized cancer vaccines, including a melanoma vaccine, to individual patients and monitors their immune response after treatment.

ODC brings personalized therapies from early-stage clinical trials to marketing approval and commercial distribution. The technology to produce the cancer vaccines is based on the ongoing work at Baylor Institute for Immunology Research under the supervision of Jacques Banchereau, Ph.D. and Karolina Palucka, M.D., Ph.D.

ODC cancer vaccines are produced by removing dendritic cell precursors from a patient, culturing and loading these cells with the tumor antigens, and then reintroducing them into the same patient. ODC Therapy Inc. is a privately held company owned by Baylor Health Care System.

Click here to see a list of inventions available for licensing.

Click here if you are a BRI investigator and would like to report an invention.